---
title: "U.S. stock market intraday update: Intellia Therap up 7.46%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/247851950.md"
description: "Intellia Therap rose 7.46%; ProKidney rose 39.95%, with a transaction volume of USD 865 million; Calidi Biotherapeutics rose 210.36%, with a transaction volume of USD 322 million; Abbvie rose 0.18%, with a transaction volume of USD 188 million, and a market capitalization of USD 335.7 billion"
datetime: "2025-07-09T14:47:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/247851950.md)
  - [en](https://longbridge.com/en/news/247851950.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/247851950.md)
generator: "portal-rs"
---

# U.S. stock market intraday update: Intellia Therap up 7.46%

**U.S. Stock Market Midday Update**

Intellia Therapeutics, up 7.46%, with increased trading volume. Based on recent important news:

1.  On July 3, Jesse Goodman, a director of Intellia Therapeutics, sold common stock of the company, which may have raised market concerns about internal confidence, leading to stock price fluctuations.

2.  On July 4, Eliana Clark, the Chief Technology Officer of Intellia, also reported selling common stock, further exacerbating market doubts about the company's future performance.

3.  On July 4, Michael P. Dube, the Chief Accounting Officer of Intellia, similarly sold common stock, and the consecutive executive sell-offs negatively impacted investor confidence.

**Stocks with High Trading Volume in the Industry**

ProKidney, up 39.95%, with a trading volume of $865 million. Based on recent important news:

1.  On July 8, ProKidney announced the Phase II results of the REGEN-007 trial, showing that Rilparencel significantly improved the eGFR slope in chronic kidney disease patients, driving the stock price up 39.95%.

2.  On July 8, the company confirmed no serious adverse events, enhancing confidence in the Phase III trial design, with a positive market reaction.

3.  On July 9, management announced an upcoming meeting with the FDA to discuss the possibility of accelerated approval, further boosting investor confidence.

Calidi Biotherapeutics, up 210.36%, with a trading volume of $322 million. Based on recent important news:

1.  On July 8, Calidi Biotherapeutics published an editorial in NetworkNewsWire, increasing market attention, and the stock price surged by 210.36%.

2.  On July 8, investors held an optimistic view on Calidi's future development, driving increased trading volume.

3.  On July 8, positive sentiment in the biotechnology sector further propelled Calidi's stock price upward.

AbbVie, up 0.18%, with increased trading volume. Based on recent important news:

1.  On July 9, analysts rated AbbVie as a moderate buy, but five other stocks were considered more attractive, affecting market confidence and causing stock price fluctuations.

2.  On July 8, the prospects of CAR-T cell therapy in autoimmune diseases were viewed positively, boosting related companies' stock prices.

3.  On July 7, the investment environment in the innovative drug sector improved, with institutions increasing their positions, leading to positive market expectations.

**Stocks with High Market Capitalization in the Industry**

AbbVie, up 0.18%, with a market capitalization of $335.7 billion. Based on recent important news:

1.  On July 9, analysts believed AbbVie's investment value was less attractive than five other stocks, leading to insufficient market confidence and stock price fluctuations

2.  On July 9th, changes in the investment structure of the innovative drug industry, with institutions increasing their positions, drove stock prices up.

3.  On July 7th, breakthroughs in CAR-T cell therapy in the field of autoimmune diseases raised market expectations for Abbvie

### Related Stocks

- [NTLA.US](https://longbridge.com/en/quote/NTLA.US.md)
- [CLDI.US](https://longbridge.com/en/quote/CLDI.US.md)
- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)

## Related News & Research

- [Time to Nibble on MCD Stock After it Enters Oversold Territory?](https://longbridge.com/en/news/300812314.md)
- [Cathie Wood Is Buying Rocket Lab Again: Why 3 ARK ETFs Are Betting on Neutron](https://longbridge.com/en/news/300816393.md)
- [ARK's Winton says each Starship launch could add $700 million a year](https://longbridge.com/en/news/300832406.md)
- [Seagate vs. Western Digital: One Stock Is a Buy After Today's Drop, but the Other Has More Upside, According to Goldman Sachs](https://longbridge.com/en/news/300813818.md)
- [‘Watch That Cliff,’ Says Top Investor on Micron Stock](https://longbridge.com/en/news/300813618.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**